ABNX — Abionyx Pharma SA Share News
0.000.00%
Last trade - 00:00- €62.99m
- €51.30m
- €4.06m
Brief: Abionyx Pharma Initiates Discussions With Iris Pharma For Possible Strategic Deal
Brief: Abionyx Pharma Announces Positive Preclinical Results In Model Of Uveitis
Brief: Abionyx H1 Operating Loss Deepens To EUR 2.6 Mln
Brief: Abionyx Pharma Gross Cash Position At EUR 4.8 Mln At End-June
Brief: Abionyx Receives Positive Opinion On ODD Application For CER-001
Brief: Abionyx: First Patient Enrolled In Phase 2A Clinical Study With CER-001
Brief: Abionyx Pharma End-March Gross Cash Position At EUR 7.3 Mln
Brief: Abionyx Pharma Announces Strategic Partnership With GTP Biologics (Groupe Fareva) And V-Nano (Groupe VBI Therapeutics)
Brief: Abionyx Confirms Breakthrough Therapy Status of CER-001 in Kidney Diseases
Brief: ABIONYX Pharma FY Net Income Turns To Loss Of 1.9 Million Euros
Brief: ABIONYX Pharma End-December Cash And Cash Equivalents Of 9.2 Million Euros
Brief: Abionyx Initiates Phase 2A Clinical Trial With CER-001 In Septic Patients
Brief: Abionyx Pharma: Publication Of Pre-Clinical Data On CER-001
Brief: Abionyx Pharma Announces Positive Signals In ATUN For Ultra-Rare Kidney Disease
Brief: Abionyx Pharma Cash And Cash Equivalents Of EUR 8.2 Mln As Of September 30, 2020
Brief: Abionyx Pharma: Success Of Capital Increase Of 1.86 Million Euros
Brief: Abionyx Pharma H1 Operating Loss Narrows To 1.0 Million Euros
Brief: Abionyx Pharma End-June Cash Position At 8.8 Million Euros
Brief: Abionyx Pharma Reports Q1 Gross Cash Position Of 9.0 Million Euros